- Home
- DRUG vs NAMI Comparison
DRUG vs NAMI Comparison
Compare DRUG & NAMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- NAMI
- Stock Information
- Founded
- DRUG 2019
- NAMI 2014
- Country
- DRUG United States
- NAMI China
- Employees
- DRUG N/A
- NAMI N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- NAMI
- Sector
- DRUG Health Care
- NAMI
- Exchange
- DRUG Nasdaq
- NAMI NYSE
- Market Cap
- DRUG 260.6M
- NAMI 286.0M
- IPO Year
- DRUG N/A
- NAMI 2024
- Fundamental
- Price
- DRUG $39.85
- NAMI $4.14
- Analyst Decision
- DRUG Buy
- NAMI
- Analyst Count
- DRUG 1
- NAMI 0
- Target Price
- DRUG $75.00
- NAMI N/A
- AVG Volume (30 Days)
- DRUG 89.2K
- NAMI 283.6K
- Earning Date
- DRUG 02-11-2025
- NAMI 02-11-2025
- Dividend Yield
- DRUG N/A
- NAMI N/A
- EPS Growth
- DRUG N/A
- NAMI N/A
- EPS
- DRUG N/A
- NAMI 0.37
- Revenue
- DRUG N/A
- NAMI $56,127,097.00
- Revenue This Year
- DRUG N/A
- NAMI N/A
- Revenue Next Year
- DRUG N/A
- NAMI N/A
- P/E Ratio
- DRUG N/A
- NAMI $10.83
- Revenue Growth
- DRUG N/A
- NAMI 64.40
- 52 Week Low
- DRUG $0.93
- NAMI $3.70
- 52 Week High
- DRUG $79.02
- NAMI $7.75
- Technical
- Relative Strength Index (RSI)
- DRUG 51.96
- NAMI N/A
- Support Level
- DRUG $34.29
- NAMI N/A
- Resistance Level
- DRUG $42.47
- NAMI N/A
- Average True Range (ATR)
- DRUG 3.54
- NAMI 0.00
- MACD
- DRUG -0.04
- NAMI 0.00
- Stochastic Oscillator
- DRUG 61.03
- NAMI 0.00
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About NAMI JINXIN TECHNOLOGY HOLDING COMPANY SPONSORED ADS EACH REP 18 ORD SHS
Jinxin Technology Holding Co is a company which operates through its subsidiaries are principally engaged in provision of digital textbook subscription services in the People's Republic of China. The Company generates revenue by selling its content to hardware manufacturers in China whereby they are allowed to install the Company's digital educational content on the manufacturers' devices for sale to end users.